INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Challenges of Managing Clinical Trials in Urticaria in 2025

Dr. Jasmina Jankicevic

Dr. Jasmina Jankicevic

Chief Medical and Scientific Officer at Indero

Picture of 18219

18219

Indero was thrilled to mark its 25th anniversary with a special edition of our Breakfast Event at AAD 2025. Attendees joined us for Itch Insights: Hives & Highlights, where we delved into the latest insights and highlights on urticaria.

Event Highlights:

  • Explored Urticaria’s Unmet Needs: Participants gained a deeper understanding of the areas in urticaria care that require more attention and innovation.
  • Discovered Pathophysiology Updates: Attendees stayed updated on the latest research and developments in the pathophysiology of urticaria.
  • Role of Dermatologists in Clinical Trials: The event highlighted the crucial role dermatologists play in managing urticaria clinical trials.

We were honored to have Jasmina Jankicevic, MD, MSc, CCRP, Chief Medical and Scientific Officer at Indero present on Challenges of Managing Clinical Trials in Urticaria in 2025.

Watch Jasmina Jankicevic’s presentation here:

Related Video

Watch “Updates on Chronic Inducible Urticaria”

Watch “Updates on Chronic Spontaneous Urticaria“

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.